Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort

The Pharmacogenomics Journal volume 5, pages 271–275 (2005)Cite this article

Abstract

This study was designed in order to investigate the influence of the genetic polymorphism of CYP2A6 on the amount of smoking. In all, 463 French adults included in the Stanislas cohort were studied and underwent two examinations at 5 years distance (t0 and t+5 years). Information on their smoking habits was collected. They were genotyped by RFLP for the CYP2A6*1A, CYP2A6*1B and CYP2A6*4 alleles. CYP2A6*1B and CYP2A6*4 allele frequencies were 32 and 4%, respectively. The subjects carrying the CYP2A6*1B allele oxidize nicotine to cotinine faster than subjects with the CYP2A6*1A allele. The number of cigarettes smoked per day was significantly higher in the CYP2A6*1B/*1B group as compared to the CYP2A6*1A/*1A group (P=0.01 at t0; P=0.001 t+5 years), with a larger increase in their daily cigarettes consumption over the 5-year period (P=0.006). No significant difference in the smoking status was observed according to the CYP2A6 genotype. These data suggest that the CYP2A6*1B is associated with the number of cigarettes smoked per day.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Rautio A . Polymorphic CYP2A6 and its clinical and toxicological significance. Pharmacogenom J 2003; 3: 6–7.

    Article  Google Scholar 

  2. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72–78.

    Article  CAS  Google Scholar 

  3. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF . Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14: 615–626.

    Article  CAS  Google Scholar 

  4. Ariyoshi N, Takahashi Y, Miyamoto M, Umetsu Y, Daigo S, Tateishi T et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics 2000; 10: 687–693.

    Article  CAS  Google Scholar 

  5. Oscarson M . Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29: 91–95.

    CAS  PubMed  Google Scholar 

  6. Oscarson M, Mclellan RA, Gullsten H, Agundez JA, Benitez J, Rautio A et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460: 321–327.

    Article  CAS  Google Scholar 

  7. Kwon JT, Nakajima M, Chai S, Yom YK, Kim HK, Yamazaki H et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 2001; 11: 317–323.

    Article  CAS  Google Scholar 

  8. Pianezza ML, Sellers EM, Tyndale RF . Nicotine metabolism defect reduces smoking. Nature 1998; 393: 750.

    Article  CAS  Google Scholar 

  9. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 747–755.

    Article  CAS  Google Scholar 

  10. Gu DF, Hinks LJ, Morton NE, Day IN . The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64: 383–390.

    Article  CAS  Google Scholar 

  11. London SJ, Idle JR, Daly AK, Coetzee GA . Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353: 898–899.

    Article  CAS  Google Scholar 

  12. Loriot MA, Rebuissou S, Oscarson M, Cenee S, Miyamoto M, Ariyoshi N et al. Genetic polymorphisms of cytochrome P450 2A6 in a case–control study on lung cancer in a French population. Pharmacogenetics 2001; 11: 39–44.

    Article  CAS  Google Scholar 

  13. Vasconcelos GM, Struchiner CJ, Suarez-Kurtz G . CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenom J 2005; 5: 42–48.

    Article  CAS  Google Scholar 

  14. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12: 627–634.

    Article  CAS  Google Scholar 

  15. Munafo MR, Clark TG, Johnstone EC, Murphy MFG, Walton RT . The genetic basis for smoking behaviour: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6: 583–597.

    Article  CAS  Google Scholar 

  16. Carter BL, Long TY, Cinciripini PM . A meta-analytic review of the CYP2A6 genotype and smoking behaviour. Nicotine Tob Res 2004; 6: 221–227.

    Article  CAS  Google Scholar 

  17. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 890–894.

    CAS  PubMed  Google Scholar 

  18. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25: 2451–2458.

    Article  CAS  Google Scholar 

  19. Messina ES, Tyndale RF, Sellers EM . A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282: 1608–1614.

    CAS  PubMed  Google Scholar 

  20. Nakajima M, Yamamoto K, Yokoi T, Nagashima K, Inoue K, Funae Y et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24: 1212–1217.

    CAS  PubMed  Google Scholar 

  21. Tyndale RF, Sellers EM . Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 2002; 24: 163–171.

    Article  CAS  Google Scholar 

  22. Kiyotani K, Fujieda M, Yamazaki H, Shimada T, Guengerich FP, Parkinson A et al. Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and caucasians. Drug Metab Pharmacokinet 2002; 17: 482–487.

    Article  CAS  Google Scholar 

  23. Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M . A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 2004; 23: 258–266.

    Article  CAS  Google Scholar 

  24. Howard LA, Sellers EM, Tyndale RF . The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 2002; 3: 185–199.

    Article  CAS  Google Scholar 

  25. Caporaso NF, Lerman C, Audrain J, Boyd NR, Main D, Issaq HJ et al. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol Biomarkers Prev 2001; 10: 261–263.

    CAS  PubMed  Google Scholar 

  26. Smits KM, Benhamou S, Garte S, Weijenberg MP, Alamanos Y, Ambrosone C et al. Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. Int J Cancer 2004; 110: 266–270.

    Article  CAS  Google Scholar 

  27. Lerman C, Berrettini W . Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet 2003; 118B: 48–54.

    Article  Google Scholar 

  28. Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT . The genetic determinants of smoking. Chest 2003; 123: 1730–1739.

    Article  CAS  Google Scholar 

  29. Wonnacott S, Sidhpura N, Balfour DJ . Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 2005; 5: 53–59.

    Article  CAS  Google Scholar 

  30. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004; 306: 1029–1032.

    Article  CAS  Google Scholar 

  31. Siest G, Visvikis S, Herbeth B, Gueguen R, Vincent-Viry M, Sass C et al. Objectives, design and recruitment of a familial and longitudinal cohort for studying gene–environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin Chem Lab Med 1998; 36: 35–42.

    CAS  PubMed  Google Scholar 

  32. Miller SA, Dyker DD, Polesky HF . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr C Sass for her close involvement in the management of the Stanislas cohort. We are also indebted to the staff of the Centre de Médecine Préventive of Vandoeuvre-lès-Nancy, France and the participants of the Stanislas cohort, who made this study possible. The Stanislas cohort study is supported by the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNAM), the Institut National de Santé et de Recherche Médicale (INSERM), the Région Lorraine, the Communauté Urbaine de Nancy, the Université Henri Poincaré Nancy I, Bayer-Pharma, Hoffmann-LaRoche, Beckman-Coulter, Biomérieux, Daiichi Pure Chemicals, Randox and Dade-Behring.

Author information

Authors and Affiliations

  1. Inserm U525, Faculté de Pharmacie, Université Henri Poincaré-Nancy1, Nancy, France

    N Gambier, A-M Batt, B Marie, M Pfister, G Siest & S Visvikis-Siest

  2. Centre de Médecine Préventive, Avenue du Doyen Parizot, Vandoeuvre-lès-Nancy, France

    G Siest & S Visvikis-Siest

Authors
  1. N Gambier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A-M Batt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Marie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Siest
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Visvikis-Siest
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Visvikis-Siest.

Additional information

This work was presented as a poster at Santorini Biologie Prospective Conference 2004

DUALITY OF INTEREST

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gambier, N., Batt, AM., Marie, B. et al. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J 5, 271–275 (2005). https://doi.org/10.1038/sj.tpj.6500314

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500314

Keywords

This article is cited by

Search

Advanced search

Quick links